Beating the odds with systematic individualized care: Nationwide prospective follow‐up of all patients with COVID‐19 in Iceland

Helgason, Daði; Eyþórsson, Elías; Ólafsdóttir, Linda Björk; Agustsson, Tomas Þor; Ingvarsdóttir, Steinunn; Sverrisdóttir, Sólveig H.; Ragnarsdóttir, Erla Dögg; Gottfreðsson, Magnús; Guðlaugsson, Ólafur; Pálsson, Runólfur; Ingvarsson, Ragnar Freyr

doi:10.1111/joim.13135

Cited by 24 publications

(45 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…4 5 All diagnosed individuals received regular follow-up by a COVID-19 outpatient clinic. 6 ICEBIO is a nationwide registry of patients with inflammatory arthritis treated with ts/bDMARDs. We included all patients in ICEBIO undergoing treatment at the start of the domestic outbreak.…”

mentioning

confidence: 99%

Prevalence, admission rates and hypoxia due to COVID-19 in patients with rheumatic disorders treated with targeted synthetic or biologic disease modifying antirheumatic drugs or methotrexate: a nationwide study from Iceland

et al. 2021

View full text Add to dashboard Cite

mentioning

confidence: 99%

Prevalence, admission rates and hypoxia due to COVID-19 in patients with rheumatic disorders treated with targeted synthetic or biologic disease modifying antirheumatic drugs or methotrexate: a nationwide study from Iceland

et al. 2021

View full text Add to dashboard Cite

“…Marie-Ming Aynaud 1 **, J. Javier Hernandez 1,3 **, Seda Barutcu 1 **, Ulrich Braunschweig 3,4 , Kin Chan 1 , Joel D. Pearson 1 , Daniel Trcka 1 , Suzanna L. Prosser 1 , Jaeyoun Kim 1 , Miriam Barrios-Rodiles 1 , Mark Jen 1 , Siyuan Song 4,5 , Jess Shen 1 , Christine Bruce 2 , Bryn Hazlett 2 , Susan Poutanen 2 , Liliana Attisano 4,5 , Rod Bremner 1 , Benjamin J. Blencowe 3,4 , Tony Mazzulli 2 , Hong Han 3,4 , Laurence Pelletier 1,3* , Jeffrey L. Wrana 1,3* . Supplementary Table 1 (Fig.…”

Section: Detection Of Sars-cov-2mentioning

confidence: 99%

A Multiplexed, Next Generation Sequencing Platform for High-Throughput Detection of SARS-CoV-2

Aynaud

Hernández

Barutcu

et al. 2020

Preprint

View full text Add to dashboard Cite

Population scale sweeps of viral pathogens, such as SARS-CoV-2, that incorporate large numbers of asymptomatic or mild symptom patients present unique challenges for public health agencies trying to manage both travel and local spread. Physical distancing is the current major strategy to suppress spread of the disease, but with enormous socio-economic costs. However, modelling and studies in isolated jurisdictions suggest that active population surveillance through systematic molecular diagnostics, combined with contact tracing and focused quarantining can significantly suppress disease spread and has significantly impacted disease transmission rates, the number of infected people, and prevented saturation of the healthcare system. However, reliable systems allowing for parallel testing of 10-100,000s of patients in larger urban environments have not yet been employed. Here we describe COVID-19 screening using Systematic Parallel Analysis of RNA coupled to Sequencing (C19-SPAR-Seq), a scalable, multiplexed, readily automated next generation sequencing (NGS) platform that is capable of analyzing tens of thousands of COVID-19 patient samples in a single instrument run. To address the strict requirements in clinical diagnostics for control of assay parameters and output, we employed a control-based Precision-Recall and predictive Receiver Operator Characteristics (coPR) analysis to assign run-specific quality control metrics. C19-SPAR-Seq coupled to coPR on a trial cohort of over 600 patients performed with a specificity of 100% and sensitivity of 91% on samples with low viral loads and a sensitivity of > 95% on high viral loads associated with disease onset and peak transmissibility. Our study thus establishes the feasibility of employing C19-SPAR-Seq for the large-scale monitoring of SARS-CoV-2 and other pathogens.

show abstract

“…The copyright holder for this preprint this version posted August 11, 2020. ; https://doi.org/10.1101/2020.08.09.20171249 doi: medRxiv preprint monitored at a newly established COVID-19 outpatient clinic at Landspitali-The National University Hospital (LUH). 15,17 The contact tracing and containment strategies implemented by the Icelandic authorities rapidly curbed the epidemic, with only 4 new cases diagnosed between May 1 and 15. 14 In this paper, we describe the analysis of prospectively collected data on all SARS-CoV-2-positive patients in Iceland and characterize the epidemiology and full clinical spectrum of COVID-19 in a nationwide cohort.…”

Section: Introductionmentioning

confidence: 99%

The clinical spectrum of COVID-19: A population-based cohort study in Iceland

Eyþórsson

Helgason

Ingvarsson

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Previous studies on the epidemiology and clinical characteristics of COVID-19 have generally been limited to hospitalized patients. The aim of this study was to describe the complete clinical spectrum of COVID-19, based on a nationwide cohort with extensive diagnostic testing and a rigorous contact tracing approach. Methods: A population-based cohort study examining symptom progression using prospectively recorded data on all individuals with a positive test (RT-PCR) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) who were enrolled in a telehealth monitoring service provided to all identified cases in Iceland. Symptoms were systematically monitored from diagnosis to recovery. Results: From January 31 to April 30, 2020, a total of 45,105 individuals (12% of the Icelandic population) were tested for SARS-CoV-2, of whom 1797 were positive, yielding a population incidence of 5 per 1000 individuals. The most common presenting symptoms were myalgia (55%), headache (51%), and non-productive cough (49%). At the time of diagnosis, 5.3% of cases reported no symptoms and 3.1% remained asymptomatic during follow-up. In addition, 216 patients (13.8%) and 349 patients (22.3%) did not meet the case definition of the Centers for Disease Control and Prevention and the World Health Organization, respectively. The majority (67.5%) of patients had mild symptoms throughout the course of the disease. Conclusion: In the setting of broad access to diagnostic testing, the majority of SARS-CoV-2-positive patients were found to have mild symptoms. Fever and dyspnea were less common than previously reported. A substantial proportion of patients did not meet recommended case definitions at the time of diagnosis.

show abstract

Beating the odds with systematic individualized care: Nationwide prospective follow‐up of all patients with COVID‐19 in Iceland

Cited by 24 publications

References 2 publications

Prevalence, admission rates and hypoxia due to COVID-19 in patients with rheumatic disorders treated with targeted synthetic or biologic disease modifying antirheumatic drugs or methotrexate: a nationwide study from Iceland

Prevalence, admission rates and hypoxia due to COVID-19 in patients with rheumatic disorders treated with targeted synthetic or biologic disease modifying antirheumatic drugs or methotrexate: a nationwide study from Iceland

A Multiplexed, Next Generation Sequencing Platform for High-Throughput Detection of SARS-CoV-2

The clinical spectrum of COVID-19: A population-based cohort study in Iceland

Contact Info

Product

Resources

About